Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting HER2 beyond breast cancer.
Bhatnagar S, Tushir-Singh J. Bhatnagar S, et al. Among authors: tushir singh j. Mol Cell Oncol. 2019 Mar 20;6(3):1571984. doi: 10.1080/23723556.2019.1571984. eCollection 2019. Mol Cell Oncol. 2019. PMID: 31131305 Free PMC article.
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
Shivange G, Urbanek K, Przanowski P, Perry JSA, Jones J, Haggart R, Kostka C, Patki T, Stelow E, Petrova Y, Llaneza D, Mayo M, Ravichandran KS, Landen CN, Bhatnagar S, Tushir-Singh J. Shivange G, et al. Among authors: tushir singh j. Cancer Cell. 2018 Aug 13;34(2):331-345.e11. doi: 10.1016/j.ccell.2018.07.005. Cancer Cell. 2018. PMID: 30107179 Free PMC article.
Arming "old guards" with "new dual-targeting weapons".
Lum LG, Tushir-Singh J. Lum LG, et al. Among authors: tushir singh j. Cancer Cell. 2021 May 10;39(5):604-606. doi: 10.1016/j.ccell.2021.04.010. Cancer Cell. 2021. PMID: 33974858 Free article.
Bispecific antibodies for the treatment of breast cancer.
Dillon PM, Tushir-Singh J, Lum LG. Dillon PM, et al. Among authors: tushir singh j. Expert Opin Biol Ther. 2022 Aug;22(8):1017-1027. doi: 10.1080/14712598.2021.1922665. Epub 2021 May 9. Expert Opin Biol Ther. 2022. PMID: 33896311 Review.
12 results